3 | P a g e Coccia M. (2019) A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis management of severe aortic stenosis for patients is surgical aortic valve replacement (SAVR). However, an emerging technology, alternative to SAVR, is transcatheter aortic valve implantation (TAVI) that is, more and more, a routinely performed technique in cardiology worldwide (Sedeek et al., 2019) .
Although several contributions in these fields of research, the behavior and characteristics of new medical technology, considering scientific and innovative production, which is generating industrial and corporate in clinical practice are hardly known. In particular, this study addresses some basic questions:
 what are the degree and rate at which new technology of TAVI is adopted when it attempts in substituting for existing technology of SAVR?
 What are the evolutionary properties of TAVI in a setting of competition between technologies in clinical practice of cardiology?  And finally, what are the economic consequences of new technology TAVI for management of AS in health institutions?
Next sections endeavor to explain how emerging technology of TAVI substitutes SAVR, generating a revolution in the management of severe aortic stenosis in society. Arthur (2009, p. 15ff ) claims that one of the most important problems to understand in studies of technology is to explain how technological innovation evolves and generates social change (cf., Arthur and Polak, 2006; Basalla, 1988) 3 . Technological evolution can be explained with theories based on processes of competitive substitution of a new technology for the old one (Coccia, 2019b; Fisher and Pry, 1971; Sahal, 1981) . In particular, theories of competitive substitution between technologies show that the adoption of a new technology is associated with the nature of some comparable older technology in use (Sahal, 1981; Utterback et al., 2019) . This study focuses on competition between medical technologies in the research field of cardiology to treat Aortic Stenosis (AS) that is one of the most frequent cardiac problems in society with ageing population. Surgical aortic valve replacement (SAVR) is the traditional technique for patients with severe AS. However, the treatment option of SAVR is associated with a high risk of operative morbidity or mortality in many patients (Armoiry et al., 2018; Lemor et al., 2019) . Transcatheter aortic valve implantation (TAVI) is a less invasive medical technology, alternative to conventional technique of surgical therapy (Paparella et al., 2019) . Cribier et al. (2002) showed, for the first time in medicine, the feasibility of a percutaneous valve implantation, called TAVI in a patient with AS, providing a promising less invasive alternative treatment to SAVR technique for treating valvular heart diseases. Since 2002, this new medical technology of TAVI is growing with incremental and radical innovations that broaden its applications in clinical practice of cardiology (Bourantas and Serruys, 2014) . In fact, technological advances in artificial heart valves with new generations of product innovation have improved the medical technology of TAVI, reduced the risk of complications, allowed the treatment of complex problems in cardiology, increased the efficacy of this technique that is the best treatment option for inoperable patients and high-risk populations as well as recent studies also show potential extension in intermediate-risk patients with symptomatic aortic stenosis (cf., Martinez et al., 2019; Mäkikallio et al. 2019; Thourani et al., 2016) . This new medical technology is associated with the evolution of artificial heart valves, delivery catheters and loading systems, such as innovative products by Edwards Lifescience corporation, a worldwide leader in prosthetic valve for surgical market (Edwards Lifescience Corporation, 2019 , 2019a , 2019b Fig. 1) .
THEORETICAL FRAMEWORK
The history of this technology shows that one of the initial prostheses is the innovative product called Cribier-Edwards, produced in 2003 and consisted of a stainless-steel frame with equine pericardium valve leaflets. In 2006, it is introduced the transcatheter heart valve Edwards SAPIEN using a higher sealing cuff and bovine pericardium leaflets. In 2009, it is introduced SAPIEN XT, which consisted of cobalt chromium alloy frame and bovine pericardium leaflets. The SAPIEN 3 (S3) is the latest generation of Edwards balloon-expandable valves.
| P a g e
Coccia M. (2019) A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis Rheude et al. (2018) describe its technical characteristics:
It features a cobalt chromium alloy frame that provides a high radial strength for circularity and optimal hemodynamics, a low frame height and an open cell geometry, allowing access to coronary vessels for future interventions and an outer polyethylene terephthalate (PET) skirt to minimize paravalvular leakage (PVL). The valve tissue consists of three leaflets manufactured from bovine pericardium. Four different sizes of the S3 THV are currently available: 20mm, 23mm, 26mm and 29mm. Selection of the appropriate THV should be made according to multislice computed tomography (MSCT) annulus area-based sizing recommendations provided by the manufacturer. The treatable range of aortic annulus diameters is wide and ranges from 18.6 mm to 29.5 mm. (2019, 2019a, 2019b) Another market leader in this industry is the American enterprise Medtronic that in 2009 buys the start-up
CoreValve, giving a boost to the design of the prosthesis and the carrier catheter with new innovative products, such as CoreValve, Evolut R and Evolut PRO system (Medtronic, 2019) that is approved by U.S. Food and Drug Administration in 2019.
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The Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System each consists of a transcatheter aortic valve (TAV), a delivery catheter, and a loading system. The TAV is an artificial heart valve made of pig tissue attached to a flexible, self-expanding nickel-titanium (Nitinol) frame for support. The Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System were previously approved for the treatment of severe aortic stenosis (a narrowing of the aortic valve that restricts blood flow to aorta, the body's main artery) in patients at intermediate and greater risk for surgical therapy. This approval expands the indications for use to patients at low risk for surgical therapy…. The doctor compresses the TAV and mounts it on the end of a tube-like device called a delivery catheter. The TAV is then inserted into the body through an artery in the leg, the artery in the neck, or through a small cut between the ribs. The valve is then released from the catheter; it expands on its own, and anchors to the diseased valve. Once the new valve is in place, it functions the same as the old valve, opening and closing like a door to force the blood to flow in the correct direction… The CoreValve Evolut R and CoreValve Evolut PRO TAVs are used in patients whose own aortic heart valve is diseased due to calcium build up, which causes the valve to narrow (aortic stenosis) and restricts blood flow through the valve. As the heart works harder to pump enough blood through the smaller opening, it eventually becomes weak. This can lead to symptoms and life-threatening heart problems such as fainting, chest pain, heart failure, irregular heart rhythms (arrhythmias), or cardiac arrest. Once symptoms of severe aortic stenosis occur, over half of patients die within two (2) years if the diseased valve is not replaced. …The CoreValve Evolut R and CoreValve Evolut PRO TAVs should only be used in patients who are considered appropriate for transcatheter heart valve replacement therapy by their heart team (including a surgeon)….The CoreValve Evolut R and CoreValve Evolut PRO TAVs can improve blood flow in patients with aortic stenosis. In the clinical study, the two TAVs were shown to be reasonably safe and effective for treating patients with severe aortic stenosis without the need for open-heart surgery. The risk of death or disabling stroke at 2 years was similar in patients receiving a CoreValve Evolut R or CoreValve Evolut PRO TAV and those receiving open-heart surgery….Any procedure to replace the aortic valve carries the risk for serious complications. The serious complications associated with implanting a CoreValve Evolut R or CoreValve Evolut PRO TAV also carries the risk of serious complications such as death, stroke, acute kidney injury, heart attack, bleeding, and the need for a permanent pacemaker. For some patients with coexisting conditions or diseases, the risks may be especially high.
Moreover, the Evolut™ PRO system combines exceptional valve design and advanced sealing with an excellent safety profile ( Figure 2 ). The Evolut PRO system features an external tissue wrap added to the proven platform design. In particular, new design features provide the following sealing mechanisms:  The external wrap increases surface contact with native anatomy, providing advanced sealing  The frame oversizing and cell geometry provide consistent radial force across the treatable annulus range 7 | P a g e Coccia M. (2019) A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis CocciaLab Working Paper 2019 -No. 39/2019 Moreover, the TAVI technology of Evolut PRO system with supra-annular and self-expanding design provides the following benefits:  Less workload for the ventricle  Fewer instances of prosthesis-patient mismatch, which has been correlated to improved long-term survival 2  A large effective orifice area (EOA) provides improved flow, less resistance, and better long-term durability Finally, supra-annular valve design maximizes leaflet coaptation and promotes single-digit gradients and large EOAs. Saleem et al. (2019) argue that new technology of TAVI is comparable to SAVR in terms of short-term and mid-term mortality and neurologic events in low surgical risk patients. In this context, Ando et al. (2019) find out that emerging technology of TAVI has a significantly lower composite of all-cause mortality or disabling/major stroke at 1 year compared with treatment of SAVR in low-to-intermediate surgical risk cohort. Lemor et al. (2019) show that in patients greater than 80 years of age, new technology of TAVI is an effective and safer alternative to SAVR since it is associated with lower in-hospital mortality, lower major in-hospital complications, lower 30-day readmission rate and hospital costs (cf., Elbadawi et al., 2019) . Hence, since 2002, after the first-in-man case, new technology of transcatheter aortic valve implantation (TAVI) is generating a change of technological paradigm in clinical practice of cardiology with a revolution for the management of severe aortic stenosis, such that is a technique more and more applied in cardiac departments of hospitals worldwide.
MATERIALS AND METHODS

Model to analyze technological evolution of medical technology in valvular heart diseases
The proposed model of technological growth here analyzes a new radical technology (Kl) in relation to an established technology V. This approach is based on the biological principle of allometry that was originated in zoology to study the differential growth rates of the parts of a living organism's body in relation to the whole body (cf., Reeve and Huxley, 1945) . Sahal (1981) suggests this model to explain patterns of the diffusion of technology, providing interesting case studies in the agriculture, manufacturing, steel production, electricity generation, etc.
The model is based on following assumptions.
(1) V is established technology, such as SAVR and Kl is new technology, such as TAVI.
(2) Let Kl(t) be the level of a new technology Kl at the time t and V(t) be the level of an established technology V at the same time.
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The equation can be rewritten as:
The integral of this equation is:
The growth of V(t) can be described respectively as:
Mutatis mutandis, for new technology Kl(t) the equation is:
The logistic curve here is a symmetrical S-shaped curve with a point of inflection at 0.5K, with CocciaLab Working Paper 2019 -No. 39/2019 Solving equations [1] and [2] for t, the result is:
The expression generated is:
Equation [3] of evolutionary growth of new technology (Kl )in relation to established technology (V) in a simplified form, with some mathematical transformations, is given by:
The logarithmic form of equation [4] is a simple linear relationship: In short, the coefficient of growth B in the proposed model can be a metric for analyzing the behavior of growth of a new technology, such as TAVI, in relation to an established technology, such as SAVR, in cardiology.
 Data and their sources
The empirical analysis is based on data of ScienceDirect (2019) and its tool of Advanced Search to find scientific products that have in title, abstract or keyword the following terms:
 "transcatheter aortic valve implantation (TAVI)"  "surgical aortic valve replacement (SAVR)" Scientific products are a main proxy to assess the patters of technology in cardiology to treat aortic stenosis.
 Measures
 For SAVR, number of articles and all scientific products in this scientific and technology field (articles, conference papers, conference reviews, book chapters, short surveys, letters, etc.), 1948-2018 period.
 For TAVI, number of articles and all scientific products in this scientific and technology field (articles, conference papers, conference reviews, book chapters, short surveys, letters, etc.), 1993-2018 period. This study also analyzes the evolution of these technologies TAVI and SAVR considering the scientific production in these research fields as a function of time on a semilogarithmic graph.
Model is specified as follows:
spy is scientific production in the research field y (i.e., TAVI or SAVR)
0 is a constant 1 is the coefficient of regression t is error term
From this model, we also generate predicted values, residuals, and prediction intervals.
Finally, the technological forecasting of TAVI and SAVR technologies is performed as follows: the procedure selects Time as independent variable, whereas dependent variable is scientific production of TAVI and SAVR, and then we use all cases to predict values using the prediction from estimation period through last case in the SPSS Figure 9 . Technological forecasting of TAVI technology Note. Predict from estimation period through last case, it predicts values for all cases, based on the cases in the estimation period in SPSS software.
The comparative analysis of the coefficient of regression based on case sequence shows that SAVR technology has a forecasted magnitude of growth equal to 16.08, whereas TAVI has a predicted level of growth of 83.79. These results further suggest a technological forecasting in cardiology oriented towards a scientific and technological growth of TAVI technology in clinical practice.
Using the sequence chart of predicted values and prediction interval at 95% of the scientific production for TAVI and SAVR, in natural logarithm, based on curve fit of linear model, results reveal that SAVR is a technology in maturity phase, whereas new technology of TAVI is in the technological phase of growth ( Figure 10 ).
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-"learning via diffusion" (Sahal, 1981, p. 114, Italics added) in which the increased adoption of TAVI technology supports the path for improvement in its technical characteristics (i.e., technological advances).
-"diffusion by learning" that improvement in the technical characteristics of TAVI technology enhances the scope for its adoption over the course of time (cf., Sahal, 1981, p. 114 
DISCUSSION AND LIMITATIONS
The concept of competition is frequently used to explain the diffusion and evolution of innovation and technology in industrial economics (Fisher and Pry, 1971; Porter, 1980; Utterback et al., 2019) . The competition between technologies leads to a process of disruptive creation that generates industrial and corporate change over time (Calvano, 2006; Coccia, 2018; Coccia, 2019b) . In particular, when comparable technologies do exist, each technology tends to affect the behavior and evolutionary pathway of other technologies (Coccia, , 2019b . Pistorius and Utterback (1997) argue that emerging technologies often supplant for more mature technologies in markets. The dynamics between technologies is usually referred to as competition that leads to the dominance of a new technology on another one in turbulent markets (cf., Berg et al., 2019) . Fisher and Pry (1971, p. 88 ) state that:
"The speed with which a substitution takes place is not a simple measure of the pace of technical advance . . . . it is, rather a measure of the unbalance in these factors between the competitive elements of the substitution". In general, competition is often embodied in substitutes, which have a powerful force in markets to improve products and processes and generate technical, economic and social change. Porter (1980) considers substitutes as one of the five forces of industrial competition.
In cardiology, TAVI technology is generating a process of actual substitution for the old SAVR technique and, as a consequence, technical, industrial and corporate change in medical sectors.
Results of empirical analysis here suggest some properties and predictions: This study may be basic in modern economic systems of rising healthcare costs, because policy-makers and clinicians must make, more and more, difficult decisions regarding resource allocation to increase organizational efficiency and improve health of patients, reducing related risks. New technology TAVI has reimbursement that, in 2010s, is restricted to high-risk and inoperable patients only. However, Ando et al. (2019) argue that medical technology TAVI has significantly lower all-cause mortality or disabling/major stroke and disabling/major stroke compared with SAVR also in low-to-intermediate surgical risk patients at 1 year. Zhou et al. (2019) argue that TAVI in intermediate-risk patients has a higher immediate procedural costs than SAVR, driven primarily by the cost of the transcatheter valve (about $33,000) but this was offset by a shorter length of hospitalization following TAVI, such that the combined cost of initial procedure and hospitalization in TAVI was lower than SAVR. In general, medical technology TAVI is likely to be highly cost-effective compared to SAVR in intermediate-risk patients with severe aortic stenosis (AS). In particular, TAVI using the third-generation SAPIEN 3 and Evolut PRO system would be cost-effective compared to SAVR in treatment of intermediate-risk patients with severe symptomatic AS. Moreover, over a ten-year horizon, medical technology SAPIEN 3 TAVI is associated with greater quality adjusted life expectancy and lower long-term costs compared with SAVR technology. Goodall et al. (2019) (2019) argue that structural valve deterioration is significantly higher in SAVR at 6 years. Another concern is the subclinical leaflet thrombosis that has been reported to be higher in TAVI than SAVR and possibly associated with worse outcomes. Ando et al. (2019) also show that stroke remains to be a major perioperative issue both TAVI and SAVR. Mäkikallio et al. (2019, p. 277 ) also reveal that several issues will play a key role in expanding TAVI indication in low-and intermediate-risk patients, such as valve durability, need for permanent pacemaker, valve performance as well as optimal antithrombotic or anticoagulation medications are questions needed to be answered when expanding TAVI technology to low-risk patient populations (Terré et al., 2017; cf., Chakos et al., 2017) . Another practical issue to be solved is whether TAVI is to replace SAVR among younger patient population because of a relatively high permanent pacemaker implantation rate for some TAVI technological devices (van Rosendael et al., 2018) . In short, since the short-term TAVI results in terms of mortality, stroke, valve performance and vascular complications have Coccia M. (2019) A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis CocciaLab Working Paper 2019 -No. 39/2019 been excellent, now the main attention is directed to long-term durability of TAVI technological valves and patients with low-intermediate surgical risks. To sum up, Table 6 shows main pros and cons of medical technology of TAVI in clinical practice. In general, the study suggests how the competition between technologies generates technological and industrial change in markets, such as in cardiology. These results here show that competition between SAVR and TAVI technology is generating a corporate change in health institutions for the management of aortic stenosis. Findings here can support innovation strategy of hospitals on critical decisions of when to invest in R&D of new TAVI technologies, abandon the old SAVR technology or pursue an intermediate level of R&D investment between old and new technology for sustaining and safeguarding cost-effectiveness of medical institutions and health of patients.
The study here is a reasonable starting point for understanding behavior and characteristics of these new medical technologies in cardiology. However, we know, de facto, that other things are often not equal over time and space in the domain of technology. Overall, then, the study here may lay the foundation for development of more sophisticated analyses at the intersection between economics of innovation and medical economics to explain technological forecasting of new technology and support strategic management of hospitals and research labs. In fact, these findings here can encourage further exploration in the terra incognita of the competition between new and established technologies in medicine that generates disruptive creation for technological and social change in society. Future efforts in this research field will be also directed to provide further empirical evidence, also considering dependency-network framework between technologies to better explain the nature and behavior of new technologies in complex organizations, such as medical institutions (cf., Iacopini et al., 2018) . To conclude, the study of new technology in medicine with pros and cons of short-, medium-, long term for institutions and individuals is a non-trivial exercise. In fact, Wright (1997 Wright ( , p. 1562 properly claims that: "In the world of technological change, bounded rationality is the rule."
